Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Aytu Biopharma (AYTU) over the last 6 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Other Accumulated Expenses fell 75.07% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 75.07%. This contributed to the annual value of $3.4 million for FY2025, which is 62.30% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Other Accumulated Expenses is $2.0 million, which was down 41.79% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Other Accumulated Expenses ranged from a high of $9.2 million in Q4 2023 and a low of $2.0 million during Q3 2025.
  • Over the past 3 years, Aytu Biopharma's median Other Accumulated Expenses value was $7.5 million (recorded in 2023), while the average stood at $6.9 million.
  • In the last 5 years, Aytu Biopharma's Other Accumulated Expenses surged by 619.37% in 2021 and then slumped by 75.07% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Other Accumulated Expenses stood at $3.2 million in 2021, then soared by 146.86% to $7.8 million in 2022, then grew by 17.91% to $9.2 million in 2023, then decreased by 23.04% to $7.1 million in 2024, then plummeted by 75.07% to $2.0 million in 2025.
  • Its Other Accumulated Expenses stands at $2.0 million for Q3 2025, versus $3.4 million for Q2 2025 and $5.1 million for Q1 2025.